ibrutinib CLL
Selected indexed studies
- Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. (Blood, 2022) [PMID:35196370]
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (N Engl J Med, 2018) [PMID:30501481]
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. (Blood Cancer J, 2021) [PMID:33927183]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (2018) pubmed
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2023) pubmed
- Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. (2022) pubmed
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. (2021) pubmed
- Ibrutinib in CLL/SLL: From bench to bedside (Review). (2019) pubmed
- Targeting BTK in CLL: Beyond Ibrutinib. (2019) pubmed
- Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. (2022) pubmed
- Ibrutinib dose modifications in the management of CLL. (2020) pubmed
- Ibrutinib reversal of immune exhaustion in CLL. (2024) pubmed
- Ibrutinib frontline in young patients with CLL. (2022) pubmed